Menu Search
Equities

1933 Industries Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TGIFF:PKC

1933 Industries Inc

Actions
  • Price (USD)0.0077
  • Today's Change0.000 / -3.53%
  • Shares traded30.20k
  • 1 Year change+173.21%
  • Beta1.8942
Data delayed at least 15 minutes, as of Feb 13 2026 19:51 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

1933 Industries Inc. is a Canada-based licensed wholesale producer, focused on the cultivation and extraction of a portfolio of cannabis consumer products in a variety of formats under its flagship brands, Alternative Medicine Association and Level X. Its product offerings are cultivated at its 68,000 sq. ft. indoor facility and marketed directly to retail dispensaries. The Company operates through three segments: Alternative Medicine Association LLC (AMA), Infused Mfg LLC (Infused MFG), and Corporate. Its AMA segment is focused on the cultivation and sale of medical and adult use cannabis products. Its Infused MFG segment is focused on the manufacturing of hemp-derived cannabidiol (CBD) products. The Company owns 100% of AMA, and 100% of Infused MFG LLC. AMA’s wholesale cannabis products include craft-style cannabis, infused pre-rolls, full-spectrum oils, distillates, proprietary blends of terpenes, vaporizer products and boutique concentrates.

  • Revenue in CAD (TTM)17.42m
  • Net income in CAD505.04k
  • Incorporated2018
  • Employees87.00
  • Location
    1933 Industries IncSuite 300, 1055 West Hastings StreetVANCOUVER V6E 2E9CanadaCAN
  • Phone+1 (604) 674-4756
  • Websitehttps://1933industries.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.